A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care
Time to first on-study Skeletal Related Event (SRE)
Study is event driven. May take longer than 33 months of study duration to observe 745 first on-study SREs in study population.
No
MD
Study Director
Amgen
Argentina: Ministry of Health, Australia: Therapeutic Goods Administration
20050136
NCT00321464
April 2006
July 2011
Name | Location |
---|---|
Research Site | Mesa, Arizona |
Research Site | Bentonville, Arkansas |
Research Site | Anaheim, California |
Research Site | Danbury, Connecticut |
Research Site | Washington, District of Columbia |
Research Site | Boca Raton, Florida |
Research Site | Albany, Georgia |
Research Site | Honolulu, Hawaii |
Research Site | Arlington Heights, Illinois |
Research Site | Bloomington, Indiana |
Research Site | Ames, Iowa |
Research Site | Ashland, Kentucky |
Research Site | Baton Rouge, Louisiana |
Research Site | Baltimore, Maryland |
Research Site | Beverly, Massachusetts |
Research Site | Battle Kreek, Michigan |
Research Site | Alexandria, Minnesota |
Research Site | Billings, Montana |
Research Site | Las Vegas, Nevada |
Research Site | Belleville, New Jersey |
Research Site | Albuquerque, New Mexico |
Research Site | Albany, New York |
Research Site | Asheville, North Carolina |
Research Site | Bismarck, North Dakota |
Research Site | Allentown, Pennsylvania |
Research Site | Charleston, South Carolina |
Research Site | Chattanooga, Tennessee |
Research Site | Abilene, Texas |
Research Site | Ivins, Utah |
Research Site | Abington, Virginia |
Research Site | Auburn, Washington |
Research Site | Clarksburg, West Virginia |
Research Site | Appleton, Wisconsin |